The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Abstract
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract. Collectively they are termed inflammatory bowel disease (IBD) and it is estimated that 1.5 million Americans (1) suffer from UC and CD. Their etiologies are unknown, although both are thought to arise from a disordered immune response to the gut contents in genetically predisposed individuals (1). The characteristics of the inflammatory response are different, with CD typically causing transmural inflammation and occasionally associated with granulomas, whereas in UC the inflammation is usually confined to the mucosa. Both UC and CD exhibit a relapsing and remitting course and there is a significant, often dramatic, reduction in quality of life during exacerbations of the disease (2). This has an impact on psychological health, with active IBD patients experiencing greater levels of distress and feelings of lack of sense of self-control compared with the normal population and patients with inactive IBD (3,4). Extrapolation from US administrative claims databases suggests that IBD is responsible for 2.3 million physician visits (5), 180,000 hospital admissions (6), and costs $6.3 billion (7) annually. There have been recent guidelines on the management of both UC (8) and CD (9) that direct the clinician on diagnosis and treatment. Approximately 33% of the cost of IBD is due to medical therapy (7), and given the substantial clinical burden and economic cost of IBD it is important to establish the effectiveness of current medical therapies in both UC and CD. Although there have been several systematic reviews on the efficacy of therapy (10,11), this is a rapidly changing field and there is a need for a comprehensive review of the literature. The American College of Gastroenterology IBD Task Force developed a protocol for systematically reviewing the data on currently available therapies for UC and CD, both in inducing remission and in preventing relapse of the disease. Evidence-based statements were then developed and the strength of recommendation for each was graded according to standard criteria. Section 1 Epidemiology of IBD Multiple studies have evaluated the epidemiology of IBD in adults from various geographic regions; most studies are from Western countries, where the incidence of IBD is highest, the existence of comprehensive databases is more common, and identification of adequately sized populations is easier (12). We have reviewed the literature on population estimates of CD and UC incidence over the past 20 years. Where there was more than one study we have taken the study with the largest population, which is most representative of the country. In the case of two studies of similar size we have evaluated the most recent data. We identified 35 studies (13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47) that provided data on incidence of CD and/or UC. In the US estimates of CD, incidence varies between 6 (13) and 8 (14) per 100,000, with a prevalence of 100 (13) to 200 (12) per 100,000. For UC, the incidence in the United States ranges between 9 (14) and 12 (13), with a prevalence of 205 (13) to 240 (12) per 100,000. Incidence estimates for other countries are given in Table 1. Geographical variation suggests that CD has a higher incidence in industrialized countries and higher rates in the West than in the East (Figure 1a). There also appears to be a North–South gradient with a strong correlation between degrees latitude and CD incidence when the Western Hemisphere and Western Europe are evaluated (Figure 2a). This North–South gradient also exists within an individual country, with CD being less common in the southern United States (12) and in the south of France (32). CD also has a high incidence in New Zealand, suggesting that the disease more common the the is from the There be an to CD that is more in a more similar exists for UC (Figure although the North–South gradient is (Figure Incidence of CD and UC variation in incidence rates for inflammatory bowel disease. Incidence rates for Crohn's disease. Incidence rates for ulcerative per in inflammatory bowel disease incidence rates with degrees latitude from the in Crohn's disease incidence in ulcerative colitis incidence has been in incidence over in most countries (Figure although it to have a in the United States and the Incidence rates are also over for UC, although the of is less (Figure rates to have a in the United States This be due to of is more to a in the that to CD. The of this in inflammatory bowel disease incidence rates over Incidence of Crohn's disease over Incidence of ulcerative colitis over of for CD has been although the disease be The diagnosis of UC also most of and then the incidence Western studies that CD is more common in with a of and a on of CD is a an between and CD in the in is a in the West and in the East CD be more common in The incidence of UC h
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–287 of 287
Rasmussen, S. N., Lauritsen, K., Tage‐Jensen, U., Nielsen, O. H., Bytzer, P., Jacobsen, O., Ladefoged, K., VILIEN, M., Binder, V., Rask-Madsen, J., et al. (1987) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528708991929 · Cited by 131
A review of associations between Crohn’s disease and consumption of sugars
Riordan, A. M., Ruxton, C. H. S., & Hunter, J. (1998) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1600556 · Cited by 130
THE TREATMENT OF CHRONIC ULCERATIVE COLITIS WITH 6‐MERCAPTOPURINE
Bean, R. H. D. (1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1962.tb20590.x · Cited by 130
Buttgereit, F., Saag, K. G., Cutolo, M., da Silva, J. A. P., & Bijlsma, J. W. J. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510017706 · Cited by 127
Winter, T. A., Wright, J., Ghosh, S. K., Jahnsen, J., Innes, A., & Round, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02285.x · Cited by 125
Inflammatory bowel disease in Iceland, 1990-1994: a prospective, nationwide, epidemiological study
Björnsson, S., & Jóhannsson, J. H. (2000) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200012010-00007 · Cited by 125
Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month study
Ferguson, Campieri, M., Doe, Persson, Nygård, & THE GLOBAL BUDESONIDE STUDY GROUP (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00285.x · Cited by 124
Tremaine, W. J., Hanauer, S. B., Katz, S., Winston, B., Levine, J. G., Persson, T., & Persson, A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05835.x · Cited by 121
Self-citationLymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?
Jones, J., & Loftus, E. V. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20211 · Cited by 120
Ott, C., Obermeier, F., Thieler, S., Kemptner, D., Bauer, A., Schölmerich, J., Rogler, G., & Timmer, A. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282f97b33 · Cited by 114
Klement, E., Lysy, J., Hoshen, M., Avitan, M., Goldin, E., & Israeli, E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01905.x · Cited by 114
Hawkey, C., Dubé, L. M., Rountree, L., Linnen, P., & Lancaster, J. F. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9041232 · Cited by 114
Kruis, W., Schreiber, S., Theuer, D., Brandes, J.-W., Schütz, E., Howaldt, S., Krakamp, B., Hämling, J., Mönnikes, H., Koop, I., et al. (2001) · Gut · doi:10.1136/gut.49.6.783 · Cited by 112
Prantera, C., Kohn, A., Mangiarotti, R., Andreoli, A., & Luzi, C. (1994) · PubMed · Cited by 112
Cortot, A., Colombel, J.-F., Rutgeerts, P., Lauritsen, K., Malchow, H., Hämling, J., Winter, T. A., Gossum, A. V., Persson, T., & Pettersson, E. (2001) · Gut · doi:10.1136/gut.48.2.186 · Cited by 110
The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis
Sood, A., Kaushal, V., Midha, V., Bhatia, K. L., Sood, N., & Malhotra, V. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200034 · Cited by 109
Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events
Hansen, R. A., Gartlehner, G., Powell, G. E., & Sandler, R. S. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.016 · Cited by 108
Groß, V., Andus, T., Caesar, I., Bischoff, S. C., Lochs, H., Tromm, A., Schulz, H. J., Bär, U., Weber, A., Gierend, M., et al. (1996) · PubMed · Cited by 108
Gross, V., Andus, T., Ecker, K. W., Raedler, A., Loeschke, K., Plauth, M., Rasenack, J. W. F., Weber, A., Gierend, M., Ewe, K., et al. (1998) · Gut · doi:10.1136/gut.42.4.493 · Cited by 107
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Mantzaris, G. J., Archavlis, E., Christoforidis, P., Kourtessas, D., Amberiadis, P., Florakis, N., Petraki, K., Spiliadi, C., & Triantafyllou, G. (1997) · PubMed · Cited by 106
Hench, P. S., Slocumb, C. H., Barnes, A. R., Smith, H. L., Polley, H. F., & Kendall, E. C. (1949) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)08438-1 · Cited by 106
Review article: appropriate use of corticosteroids in Crohn’s disease
Irving, P. M., Gearry, R. B., Sparrow, M., & GIBSON, P. R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03379.x · Cited by 104
Bossa, F., Fiorella, S., Caruso, N., Accadia, L., Napolitano, G., Valvano, M. R., Andriulli, A., & Annese, V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.01007.x · Cited by 104
The Role of the Fecal Stream in Crohnʼs Disease: An Historical and Analytic Review
Janowitz, H. D., Croen, E. C., & Sachar, D. B. (1998) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199802000-00006 · Cited by 103
Fockens, P., Mulder, C. J. J., Tytgat, G. N. J., Blok, P., & Ferwerda, J. (1995) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199511000-00003 · Cited by 103
Methotrexate for induction of remission in ulcerative colitis
Chande, N., Wang, Y., MacDonald, J. K., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006618.pub3 · Cited by 103
Reinisch, W., Panés, J., Lémann, M., Schreiber, S., Feagan, B. G., Schmidt, S. L., Sturniolo, G. C., Mikhailova, T. L., Alexeeva, O., Sanna, L., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02024.x · Cited by 102
Sinčić, B. M., Vucelic, B. N., Peršić, M., Brnčić, N., Jurišić‐Eržen, D., Radaković, B., Mičović, V., & Štimac, D. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520500320094 · Cited by 102
D’Haens, G., Fedorak, R. N., Lémann, M., Feagan, B. G., Kamm, M. A., Cosnes, J., Rutgeerts, P. J., Marteau, P. R., Travis, S. P. L., Schölmerich, J., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21034 · Cited by 101
Self-citationThe molecular complexity of glucocorticoid actions in inflammation — a four-ring circus
Goulding, N. J. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.06.009 · Cited by 98
Basic Epidemiology of Inflammatory Bowel Disease in Puerto Rico
Appleyard, C. B., Hernández, G., & Ríos‐Bedoya, C. F. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200403000-00007 · Cited by 97
Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania
Gheorghe, C., Pascu, O., Gheorghe, L. S., Iacob, R. A., Dumitru, E., Tantau, M. V., Vădan, R., Goldiș, A., Bălan, G. G., Iacob, S., et al. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200411000-00012 · Cited by 94
High incidence of inflammatory bowel disease in The Netherlands
Rüssel, M. G., Dorant, E., Volovics, A., Brummer, R. J., Pop, P., Muris, J. W. M., Bos, L. P., Limonard, C. B. G., & Stockbrügger, R. W. (1998) · Diseases of the Colon & Rectum · doi:10.1007/bf02236893 · Cited by 94
INTERNATIONAL MESALAZINE STUDY GROUP (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00449.x · Cited by 94
Passive Smoking and Inflammatory Bowel Disease: A Meta-Analysis
Jones, D. T., Osterman, M. T., Bewtra, M., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01999.x · Cited by 93
Ohkusa, T., Nomura, T., Terai, T., Miwa, H., Kobayashi, O., Hojo, M., Takei, Y., Ogihara, T., Hirai, S., Okayasu, I., et al. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510023648 · Cited by 93
Crohn's disease in mainland China: a systematic analysis of 50 years of research
Zheng, J. J., Xia Shuang, Z. H. U., Huangfu, Z., Zhi Xin, G. A. O., Zhi Rong, G. U. O., & Zhen, W. A. N. G. (2005) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2005.00227.x · Cited by 92
Clinical Epidemiology of Inflammatory Bowel Disease in Lebanon
Abdul-Baki, H. A., Hajj, I. I. E., El-Zahabi, L. M., Azar, C. R., Aoun, E. G., Zantout, H., Nasreddine, W., Ayyach, B., Mourad, F. H., Soweid, A., et al. (2006) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20022 · Cited by 90
Epidemiology and outcome of Crohn’s disease in a teaching hospital in Riyadh
Alghamdi, A., Al-Mofleh, I. A., Al-Rashed, R. S., Al-Amri, S. M., Aljebreen, A., Isnani, A. C., & El-Badawi, R. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i9.1341 · Cited by 90
The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005
GUNESH, S., THOMAS, G. A. O., WILLIAMS, G. T., ROBERTS, A., & HAWTHORNE, A. B. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03576.x · Cited by 89
Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease
Maeda, Y., Ng, S. C., Durdey, P., et al. (2010) · British journal of surgery · doi:10.1002/bjs.7121 · Cited by 88
Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone, S., Petrillo, Имбеси, CERUTTI, BOLLANI, & Porro, B. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00473.x · Cited by 84
Controlled trial of antimycobacterial therapy in Crohn's disease: Clofazimine versus placebo
Afdhal, N. H., Long, A., Lennon, J. R., Crowe, S. F., & O’Donoghue, D. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01298873 · Cited by 84
Paoluzi, O. A., Iacopini, F., Pica, R., Crispino, P., Marcheggiano, A., Consolazio, A., Rivera, M., & Paoluzi, P. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02458.x · Cited by 84
Sandborn, W. J., COLOMBEL, J. ‐., Frankel, M. B., Hommes, D. W., Lowder, J. N., Mayer, L., Plevy, S. E., Stokkers, P. C. F., Travis, S. P. L., Assche, G. V., et al. (2010) · Gut · doi:10.1136/gut.2009.205443 · Cited by 82
Self-citationBudesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trial
Hanauer, S. B., Sandborn, W. J., Persson, A., & Persson, T. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02338.x · Cited by 80
Self-citationKruis, W., Jonaitis, L. V., Pokrotnieks, J., Mikhailova, T. L., Horynski, M., Bátovský, M., Lozynskyy, Y., Zakharash, Y. M., Rácz, I. A., Kull, K., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04537.x · Cited by 79
VILIEN, M., Dahlerup, J. F., Munck, L. K., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01944.x · Cited by 77
Ito, H., Iida, M., Matsumoto, T., Suzuki, Y., Sasaki, H., Yoshida, T., Takano, Y., & Hibi∥, T. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21193 · Cited by 76
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis
Baumgart, D. C., MacDonald, J. K., & Feagan, B. G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007216 · Cited by 76
Oral tobramycin in ulcerative colitis: effect on maintenance of remission
Lobo, A., Burke, D., Sobala, G. M., et al. (1993) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1993.tb00084.x · Cited by 75
Optimum dose of olsalazine for maintaining remission in ulcerative colitis.
Travis, S. P. L., Tysk, C., de Silva, H. J., Sandberg–Gertzén, H., Jewell, D. P., & Järnerot, G. (1994) · Gut · doi:10.1136/gut.35.9.1282 · Cited by 74
Riis, P. M., ANTHONISEN, P., Hr, W., Folkenborg, O., Bonnevie, O., & Binder, M. J. (1973) · PubMed · Cited by 74
Bossa, F., Latiano, A., Rossi, L., Magnani, M., Palmieri, O., Dallapiccola, B., Serafini, S., Damonte, G., Santo, E. D., Andriulli, A., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02103.x · Cited by 70
Olsalazine in maintenance of clinical remission in patients with ulcerative colitis
Wright, J. P., O'Keefe, E. A., Cuming, L., & Jaśkiewicz, K. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01296107 · Cited by 69
Review article: monitoring of immunomodulators in inflammatory bowel disease
Aberra, F. N., & Lichtenstein, G. R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02343.x · Cited by 68
Old and New Drugs Used in Rheumatoid Arthritis: A Historical Perspective
Case, J. P. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200103000-00007 · Cited by 67
Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?
Lakatos, L., & Lakatos, P. L. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042416 · Cited by 63
Treatment of Ulcerative Colitis with Antimetabolites
Bean, R. H. D. (1966) · BMJ · doi:10.1136/bmj.1.5495.1081 · Cited by 62
The Prophylactic Effect of Salazosulphapyridine in Ulcerative Colitis during Long-Term Treatment
Riis, P., ANTHONISEN, P., Wulff, H. R., Folkenborg, O., Bonnevie, O., & Binder, V. (1973) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1973.12096672 · Cited by 61
Glucocorticoid suppression of nuclear factor-κB: a role for histone modifications
Kagoshima, M., Ito, K., Cosío, B. G., et al. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310060 · Cited by 60
Changes in Liver Biochemistry During Methotrexate Use for Inflammatory Bowel Disease
Fournier, M. R., Klein, J., Minuk, G. Y., & Bernstein, C. N. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.21 · Cited by 60
Self-citationHealth-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease
Feagan, B. G., Sandborn, W. J., Hass, S., Niecko, T., & White, J. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01508.x · Cited by 55
Self-citationFord, A. C., Guyatt, G. H., Talley, N. J., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.658 · Cited by 55
Self-citationLichtenstein, G. R., Gordon, G. L., Zakko, S. F., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04438.x · Cited by 53
Graham, M., Willey, A., Adams, J., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)27612-2 · Cited by 53
de Franchis, R., Omodei, P., Ranzi, T., Brignola, C., ROCCA, R., Prada, A., Pera, A., Vecchi, M. L., Piano, M. D., Ferrara, A. M., et al. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00212.x · Cited by 51
A population-based study on the incidence of inflammatory bowel disease in Oviedo (Northern Spain)
Rodrigo, L., Riestra, S., Niño, P., Cadahía, V., Tojo, R., Fuentes, D., Moreno, M., González-Ballina, E., & Fernández, E. (2004) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082004000500002 · Cited by 50
Review article: high‐dose aminosalicylates to induce and maintain remissions in ulcerative colitis
Hanauer, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03058.x · Cited by 47
Self-citationClinical trial: randomized study of clarithromycin versus placebo in active Crohn’s disease
Leiper, K., MARTIN, K., Ellis, A., Watson, A. J. M., Morris, A. I., & Rhodes, J. M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03661.x · Cited by 47
Oral fluticasone propionate in active distal ulcerative colitis.
Angus, P. W., Snook, J. A., Reid, M., & Jewell, D. P. (1992) · Gut · doi:10.1136/gut.33.5.711 · Cited by 46
Lauritsen, K., Laursen, L., Bukhave, K., et al. (1988) · Gut · doi:10.1136/gut.29.10.1316 · Cited by 45
Rizzello, F., Gionchetti, P., Galeazzi, R., et al. (2001) · Advances in Therapy · doi:10.1007/bf02850196 · Cited by 44
Radhakrishnan, S., Zubaidi, G., Daniel, M., et al. (2009) · Digestion · doi:10.1159/000201453 · Cited by 43
Epidemiological Features of Ulcerative Colitis in Trakya, Turkey
Tezel, A., Dökmeci, G., Eskıocak, M., Ümit, H. C., & Soylu, A. (2003) · Journal of International Medical Research · doi:10.1177/147323000303100211 · Cited by 43
Falck-Ytter, Y. T., Kunz, R., Guyatt, G. H., & Schünemann, H. J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01853.x · Cited by 37
Oral 5-ASA Therapy in Ulcerative Colitis
Sandborn, W. J. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181595b56 · Cited by 36
Self-citationRanzi, T., Bodini, P., Zambelli, A., Politi, P., Lupinacci, G., Campanini, M., Lago, A. L. D., Lisciandrano, D., & Bianchi, P. A. (1996) · PubMed · Cited by 34
Crohn’s disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995–2006)
Pavlović-Čalić, N., Salkic, N. N., Gegic, A., Smajić, M., & Alibegović, E. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-008-0493-1 · Cited by 29
Incidence of inflammatory bowel disease in the French West Indies (1997-1999)
Edouard, A., Paillaud, M., Merle, S., Orhan, C., †, M. C.-P., & Cogeag, L. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)86347-x · Cited by 28
Bresci, G., Parisi, G., & Banti, S. (1994) · PubMed · Cited by 25
Inflammatory bowel disease in Estonia: a prospective epidemiologic study 1993-1998
Salupere, R. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i3.387 · Cited by 23
Edwards, C. N., Griffith, S., Hennis, A. J. M., & Hambleton, I. R. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20495 · Cited by 23
Economou, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i38.5116 · Cited by 23
Budesonide for Crohn's disease
Seow, C. H., Benchimol, E. I., Steinhart, A. H., Griffiths, A. M., & Otley, A. R. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903124355 · Cited by 21
Latour, P., Bélaïche, J., Louis, E., et al. (1996) · PubMed · Cited by 14
Psychological Adjustment to Inflammatory Bowel Disease
Sirois, F. M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.537 · Cited by 10
Cited by
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
Self-citationMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Self-citationSunlight and Vitamin D: A global perspective for health
Wacker, M., & Holick, M. F. (2013) · Dermato-Endocrinology · doi:10.4161/derm.24494 · Cited by 1,156
Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
Self-citation
Metadata
- Authors
- Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-04
- Volume
- 106
- Pages
- S2-S25
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W1984426896
- Cited by
- 310
- References
- 287
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.